Osimertinib for Advanced Lung Cancer Treatment
Author Information
Author(s): Peng Mu-Han, Huang Yen-Hsiang, Hsu Kuo-Hsuan, Tseng Jeng-Sen, Lee Po-Hsin, Chen Kun-Chieh, Chang Gee-Chen, Yang Tsung-Ying
Primary Institution: Taichung Veterans General Hospital
Hypothesis
Does osimertinib provide different clinical outcomes when used as a second-line treatment compared to a third-line or later treatment in advanced EGFR-mutant NSCLC patients with acquired T790M mutations?
Conclusion
Osimertinib is effective as both a second-line and third-line treatment for advanced EGFR-mutant NSCLC patients with acquired T790M mutations, showing no significant difference in survival outcomes between the two treatment lines.
Supporting Evidence
- 158 patients were analyzed for the study.
- Osimertinib showed a median PFS of 10.7 months in the 2nd-line group.
- The median OS from first-line treatment was 73.2 months in the 2nd-line group.
- No significant differences in survival outcomes were found between treatment lines.
- 62.7% of patients received osimertinib as 2nd-line treatment.
- Median OS was 57.5 months for patients receiving osimertinib as ≥3rd-line treatment.
- Patients with exon 19 deletion had a trend of better PFS than those with exon 21 L858R mutation.
- Statistical analyses were performed using SPSS 23.0.
Takeaway
This study shows that a medicine called osimertinib works well for patients with a type of lung cancer, whether they take it second or later in their treatment.
Methodology
This was a single-center, observational, retrospective analysis of patients who received sequential osimertinib treatment from September 2014 to March 2023.
Potential Biases
Potential selection bias due to the retrospective nature and single-center design.
Limitations
The study was a single-center, retrospective analysis, which may introduce bias, and the findings may not be applicable to other ethnic populations.
Participant Demographics
{"median_age":62,"gender_distribution":{"female":108,"male":50},"smoking_status":{"non_smokers":137,"former_or_current_smokers":21},"clinical_stage":{"stage_IVA":60,"stage_IVB":77,"recurrence_after_surgery":21}}
Statistical Information
Confidence Interval
{"pfs":"10.7 months (95% CI, 6.1 to 15.3) for 2nd-line; 8.9 months (95% CI, 6.4 to 11.4) for ≥3rd-line","os":"73.2 months (95% CI, 47.1 to 99.3) for 2nd-line; 57.5 months (95% CI, 52.9 to 62.1) for ≥3rd-line"}
Statistical Significance
p=0.222 for PFS, p=0.123 for OS
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website